Skip to main content
. 2019 Apr 23;10(30):2855–2868. doi: 10.18632/oncotarget.26869

Table 5. RECIST response (N = 25 with evaluable disease).

Best Response #(%) Median Duration, mo (range)
CR 0 NA
PR 5 (20%) 4.5 (3.3–9.5)
SD ≥ 4 mo 11 (44%) 7.8 (4.0–11.8)
Total SD 15 (60%) 5 (3.0–11.8)
PD 5 (20%) 1.8 (1.5–2.4)
Clinical Benefit Rate (CR+ PR + SD) 20/25 (80%; for all SD) 16/25 (64%; for SD ≥ 4 mo)
Overall Response Rate (CR+PR) 5/25 (20%)

Abbreviations: pts: patients; mo: months; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NA: not applicable.